Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013911 (emaciation)
 1,059 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pharmacokinetic and clinical studies on amikacin (AMK) by intravenous drip (i.v.d.) infusion were performed, and the following results were obtained. 1. Serum concentrations of AMK were determined in 4 patients with normal renal function after 1 hour i.v.d. infusion of 200 mg of AMK. The mean peak serum concentration was 14.20 +/- 0.88 micrograms/ml at the termination of i.v.d. infusion and declined to 2.30 +/- 0.79 micrograms/ml at 4 hours later. The half-life was 1.55 +/- 0.28 hours. 2. Twenty-three patients with severe pulmonary infection received 1 hour i.v.d. infusion of 200 mg of AMK 2 to 3 times a day. Clinical response was good in 17 cases, fair in 4 and poor in 2. Thus, 73.9% of the patients responded to AMK. 3. No adverse effects were observed with the exception of tinnitus and hearing loss in 1 case. Therefore, it is thought that the i.v.d. infusion of AMK will be useful for treatment of severe infectious patients with bleeding tendency and emaciation.
 ...
PMID:[Experimental and clinical studies of intravenous infusion of amikacin in acute respiratory tract infections]. 715 53